A 28-year-old woman presented to her primary care provider with the chief report of persistent itch associated with atopic dermatitis (AD), with itch severity worst on her hands bilaterally. AD was ...
Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.
Please provide your email address to receive an email when new articles are posted on . Percentages of patients with at least one atopic comorbidity ranged from 69.9% to 75.4%. Percentages of patients ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...
Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...
What exactly is severe AD? AD is the most common type of eczema. When this eczema becomes severe, a person has patches of skin that are red, swollen, and unbearably itchy. The patches of AD can weep ...
Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.
On August 1, 2024, L'Institut national d'excellence en santé et services sociaux (INESSS) issued a positive reimbursement recommendation with conditions for Ebglyss as a first-line biological therapy ...
Atopic dermatitis, the most common type of eczema, has three distinct stages: acute, subacute, and chronic. Many dermatologists use these terms with patients to help them understand their symptoms, ...
Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...
Please provide your email address to receive an email when new articles are posted on . Food allergy rates included 38.3% with asthma and 20.4% with no asthma. Atopic dermatitis was more severe among ...
Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results